Your browser doesn't support javascript.
loading
Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous Leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later
Robles-Nasta, Max; Sánchez-Bonilla, Daniela; Gallardo-Pérez, Moisés M.; Hernández-Flores, Edgar J.; Montes-Robles, Merittzel A.; Pastelín-Martínez, María de L.; Olivares-Gazca, Juan C.; Ruiz-Delgado, Guillermo J.; Ruiz-Argüelles, Guillermo J..
Affiliation
  • Robles-Nasta, Max; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Sánchez-Bonilla, Daniela; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Gallardo-Pérez, Moisés M.; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Hernández-Flores, Edgar J.; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Montes-Robles, Merittzel A.; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Pastelín-Martínez, María de L.; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Olivares-Gazca, Juan C.; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Ruiz-Delgado, Guillermo J.; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
  • Ruiz-Argüelles, Guillermo J.; Centro de Hematología y Medicina Interna. Clínica Ruiz. Puebla. MX
Rev. invest. clín ; Rev. invest. clín;76(2): 91-96, Mar.-Apr. 2024. tab, graf
Article ي En | LILACS-Express | LILACS | ID: biblio-1569950
المكتبة المسؤولة: MX1.1
ABSTRACT
ABSTRACT

Background:

Chronic myelogenous leukemia is a neoplastic proliferation of the granulocytic series. In Mexico, chronic myelogenous leukemia accounts for approximately 10% of all leukemias. Tyrosine-kinase inhibitors are considered front-line therapy in high-income countries, whereas allogeneic hematopoietic stem cell transplantation is a recognized therapeutic approach, mainly in low- and middle-income countries.

Objective:

To analyze the overall survival of persons with chronic myelogenous leukemia who have received tyrosine-kinase inhibitors or allogeneic hematopoietic stem cell transplantation in a medical center, since 1994, and briefly discuss the current indications of these treatments in the tyrosine-kinase inhibitors era.

Methods:

We retrospectively analyzed all patients with a diagnosis of chronic myelogenous leukemia treated in a medical center between 1994 and 2023; subsets of individuals who received an allogeneic hematopoietic stem cell transplantation or tyrosine-kinase inhibitors therapy as first-line treatment were analyzed.

Results:

60 persons with chronic myelogenous leukemia were treated with allogeneic hematopoietic stem cell transplantation or tyrosine-kinase inhibitors 35 received an allogeneic hematopoietic stem cell transplantation, whereas 25 were given tyrosine-kinase inhibitors. All patients who underwent an allogeneic hematopoietic stem cell transplantation engrafted successfully, and the procedure was completed on an outpatient basis in most cases (29/35). The median survival in allogeneic hematopoietic stem cell transplantation was 78.3 months (CI 95% 0-205.6) and in persons given tyrosine-kinase inhibitors the median was not reached.

Conclusion:

Tyrosine-kinase inhibitors were significantly superior to allogeneic hematopoietic stem cell transplantation in prolonging the overall survival of persons with chronic myelogenous leukemia in our single institution experience. (Rev Invest Clin. 2024;76(2)91-6)
Key words

النص الكامل: 1 الفهرس: LILACS البلد/الأقليم حسب الموضوع: Mexico اللغة: En مجلة: Rev. invest. clín موضوع المجلة: MEDICINA السنة: 2024 نوع: Article

النص الكامل: 1 الفهرس: LILACS البلد/الأقليم حسب الموضوع: Mexico اللغة: En مجلة: Rev. invest. clín موضوع المجلة: MEDICINA السنة: 2024 نوع: Article